Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918071 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT02918071: Completed Phase 3 study of Asthma, sponsored by AstraZeneca.
NCT02918071 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 121 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02918071, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma
Primary Outcome
Patients who are still in the study is defined as patients who had been treated for the specified timepoint. A successful administration is defined as an injection completed, an answer of "Yes" to all 5 questions in the Questionnaire, and adequately passed the visual inspection and function tests.
Conditions Studied
Interventions
- BIOLOGICAL Benralizumab
Study Locations (20)
Texas
- Research Site - Boerne
- Research Site - McKinney
- Research Site - Plano
- Research Site - San Antonio
Ontario
- Research Site - Ajax
- Research Site - Burlington
- Research Site - Kanata
- Research Site - Mississauga
California
- Research Site - Northridge
- Research Site - Riverside
- Research Site - Westminster
Florida
- Research Site - Miami
- Research Site - Winter Park
Georgia
- Research Site - Albany
Minnesota
- Research Site - Minneapolis
Missouri
- Research Site - St Louis
Ohio
- Research Site - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2016-11-10 |
| Est. Completion | 2017-08-21 |
| Phase | Phase 3 |
What the finished NCT02918071 record still lists
NCT02918071 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Benralizumab is the first listed.
NCT02918071 names 20 study sites across 11 states, led by Texas, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT02918071 about?
NCT02918071 is a clinical study titled "Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home". The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administ...
What is the current status of trial NCT02918071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2016-11-10. Estimated completion is 2017-08-21.
What conditions does trial NCT02918071 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02918071?
The interventions under investigation include: Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02918071?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02918071 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02918071's enrollment target sits among peer trials
121 198th of 374 higher than 177 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI